John and Frances Angelos Law Center, Room 539
Administrative Assistant: Gloria Joy
John and Frances Angelos Law Center, Room 518
J.D., Georgetown University Law Center
M.D., State University of New York at Stony Brook School of Medicine
B.A., Johns Hopkins University
Professor Dolin is co-director of the Center for Medicine and Law. The center supports collaboration between experts in the fields of both medicine and law, and focuses its efforts on an examination of medical and legal issues from the perspective of the health-care practitioner. Professor Dolin's primary research interests are at the intersection of patent and health-care law.
The center, with the Johns Hopkins Medical Institutions, operates the JHU/UB School of Law Joint Program for Medicine and the Law. The program aims to shift the focus from the courtroom to the classroom by empowering health providers, attorneys and other stakeholders to work together in a collaborative setting on health law issues.
Before joining the University of Baltimore School of Law, Dr. Dolin held a position at George Washington University Law School as a Frank H. Marks Visiting Associate Professor of Law and an Administrative Fellow in the Intellectual Property Program. He was a law clerk to the Hon. Pauline Newman of the U.S. Court of Appeals for the Federal Circuit and the late Hon. H. Emory Widener Jr. of the U.S. Court of Appeals for the Fourth Circuit. He served as a John M. Olin Fellow in Law at Northwestern University School of Law, and as an associate in the intellectual property group of Kramer, Levin, Naftalis, and Frankel LLP.
Dubious Patent Reform, 56 B.C.L. Rev__ (forthcoming 2015).
Non-Price Competition in “Substitute" Drugs: The FTC's blind spot (working title), 59 Antitrust Bull.__ (forthcoming 2014).
Speaking of Science: Introducing Notice-and-Comment into the Legislative Process, 2014 Utah L. Rev. 243 (2014)
Resolving the Original Sin of Bolling v. Sharpe, 44 Seton Hall L. Rev. 749 (2014) .(forthcoming 2014).
Patents at the Supreme Court: It Could Have Been Worse, 2012-13 CATO Sup. Ct. Rev. 267 (2013).
Resolving the Patent-Antitrust Paradox: Promoting Consumer Welfare Through Innovation (White Paper, George Mason University Center for Protection Intellectual Property 2013).
Exclusivity Without Patents: The New Frontier of FDA Regulation for Genetic Materials, 98 Iowa L.R. 1399 (2013).
Reverse Settlements as Patent Invalidity Signals, 24 Harvard J. L. & Tech 281 (2011).
A Defense of Embryonic Stem Cell Research, 84 Ind. L.J. 1203 (2009).
Medical hope, legal pitfalls: Potential legal issues in the emerging field of oncofertility, 49 Santa Clara L. Rev. 673 (2009).
Presenter, Nautilus, Inc. v. Biosig Instruments, Inc., American University School of Law Program on Information Justice and Intellectual Property (April 28, 2014).
Presenter. Fire in the Blood Debate: Access to HIV Medications in Africa, University of Baltimore (March 31, 2014).
Presenter, Genetic Resources, Indigenous Peoples and Federal Policy, 2nd Annual Cherry Blossom Symposium &emdash; Traditional Knowledge: IP and Federal Policy, American University School of Law Program on Information Justice and Intellectual Property (March 21, 2014).
Presenter, Is IP Property or Government-Conferred Monopoly? 16th Annual Faculty Conference, Federalist Society, New York, N.Y. (Jan. 3, 2014).
Presenter, Should the US Enact Stronger Regulations Against Genetically-Modified Crops? The Pride and Purpose Debate, Hofstra, Hempstead, N.Y. (Dec. 5, 2013).
Burden of Proof in the World of Patents: Medtronic v. Boston Scientific , podcast, Federalist Society (Nov. 25, 2013).
The Myriad Decision and Patented Innovation in the Biotech Industry, podcast, Federalist Society Panel (July 11, 2013).
Patenting Human DNA: The Court’s Decision, podcast, Federalist Society (June 27, 2013).
Supreme Court's Decision in AMP v. Myriad, podcast, Federalist Society (June 19, 2013).
The Seed Patent Case: Bowman v. Monsanto, podcast, Federalist Society Panel (June 3, 2013).